A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

APRINOIA Therapeutics

Status and phase: Active, not recruiting; Phase 1

Conditions: Alzheimer Disease; Healthy Volunteers; Tauopathies

Treatments: Drug: APNmAb005; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05344989

APNmAb005-101

Details and patient eligibility

About

This is a Phase 1, first-in-human (FIH), double-blinded, placebo-controlled study where healthy subjects are randomly allocated to receive APNmAb005 or placebo. Approximately 5 dosing groups (cohorts) are planned with 8 subjects (randomized to 6 active: 2 placebo) per cohort. the starting dose of APNmAb005 is 5 mg/kg and the anticipated doses for subsequent cohorts are 10, 25, 50 and 70 mg/kg. A Safety Review Team (SRT) will review data on an ongoing basis throughout the study and before progression to the next dose level cohort.

Subjects will receive a single dose of either APNmAb005 or placebo administered as a single IV infusion on Day 1 of the study and will remain in the study center until Day 3 (48 hours after dosing). They will return to the study center for 7 outpatient visits. The duration of the study, excluding screening, is approximately 71 days.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI) of 18.5 to 32 kg/m² inclusive, at screening.
• Female subjects of childbearing potential must use an acceptable method of birth control from screening until at least 90 days after study drug dosing; OR be surgically sterile; OR be postmenopausal. All female subjects must have a negative pregnancy test at screening and before the first dose of the study drug. Female subjects must also agree to refrain from egg donation during the study and for at least 90 days after study drug dosing.
• Male subjects must agree to use a condom when sexually active with a female partner of childbearing potential during the study and for at least 90 days after study drug dosing (or be surgically sterile); OR agree to practice abstinence during the study and for at least 90 days after study drug dosing. Male subjects must also agree to refrain from sperm donation during the study and for at least 90 days after study drug dosing.
• Agree to comply with all protocol requirements.
• Provide written informed consent.

Exclusion criteria

• Unable or unwilling to undergo venipuncture or tolerate venous access, or is unable or unwilling to undergo lumbar puncture.
• Has any significant acute or chronic medical illness that would impact the subject's ability to complete all study requirements or impact assessment of study data; or subject as had a clinically significant illness within 30 days prior to study drug dosing.
• Any medical condition or documented history that is a contraindication to lumbar puncture (e.g. bleeding disorder, spinal deformity).
• Positive COVID-19 molecular diagnostic test result at screening or prior to study drug dosing; or subject has known or suspected consequence from prior COVID-19 infection.
• History of cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal or oncogenic (with the exception of resected skin basal cell carcinoma) disease within 5 years prior to screening).

NOTE: Subjects with treated stable psychiatric conditions (e.g. anxiety, depression) are not allowed.

• Clinically significant neurological or psychiatric disorder.
• Major surgery, as determined by investigator, within 4 weeks prior to study drug dosing.
• Systolic blood pressure >140 mm Hg and/or diastolic blood pressure >90 mm Hg.
• Received any vaccine or used any prescription or over-the-counter medications (except paracetamol [up to 2 g per day]), including herbal or nutritional supplements, within 14 days prior to study drug dosing.
• Consumed caffeine- or xanthine-containing products within 48 hours prior to study drug dosing.
• Subject is a smoker or has regularly used nicotine or nicotine-containing products (e.g. snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 3 months prior to study drug dosing.
• Subject is involved in vigorous or strenuous physical activity or contact sports within 24 hours prior to study drug dosing.
• Subject has donated blood or blood products >450 mL within 3 months prior to study drug dosing.

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Quadruple Blind

---

40 participants in 5 patient groups

APNmAb005 (5mg/kg) vs Placebo

Active Comparator group

Description:

Single Ascending Dose (SAD)

Treatment:

Drug: Placebo

Drug: APNmAb005

APNmAb005 (10 mg/kg) vs Placebo

Active Comparator group

Description:

Single Ascending Dose (SAD)

Treatment:

Drug: Placebo

Drug: APNmAb005

APNmAb005 (25 mg/kg) vs Placebo

Active Comparator group

Description:

Single Ascending Dose (SAD)

Treatment:

Drug: Placebo

Drug: APNmAb005

APNmAb005 (50 mg/kg) vs Placebo

Active Comparator group

Description:

Single Ascending Dose (SAD)

Treatment:

Drug: Placebo

Drug: APNmAb005

APNmAb005 (70 mg/kg) vs Placebo

Active Comparator group

Description:

Single Ascending Dose (SAD)

Treatment:

Drug: Placebo

Drug: APNmAb005